[1] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[2] |
HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao.
A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation
[J]. China Oncology, 2024, 34(9): 857-872.
|
[3] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
[4] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[5] |
GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo.
The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer
[J]. China Oncology, 2024, 34(8): 745-752.
|
[6] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[7] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[8] |
LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui.
Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy
[J]. China Oncology, 2024, 34(3): 278-285.
|
[9] |
REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng.
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
[J]. China Oncology, 2024, 34(12): 1090-1099.
|
[10] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
[11] |
WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong.
Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells
[J]. China Oncology, 2024, 34(11): 987-997.
|
[12] |
ZHANG Shaohua, LI Zhening, WANG Wei, WEI Yifan, HONG Yonggang, HAO Liqiang.
Research progress in the related treatment of KRAS mutant colorectal cancer
[J]. China Oncology, 2024, 34(10): 979-986.
|
[13] |
Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association .
Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition)
[J]. China Oncology, 2024, 34(1): 13-66.
|
[14] |
WU Han, XU Lei, WANG Miaomiao, ZHANG Ruizhe, XU Xiaoyang, GUO Ningjie, WU Shuhua.
Correlation of LC3 and the recruitment of dendritic cell and the formation of TLS in colorectal cancer and its clinical significance
[J]. China Oncology, 2023, 33(9): 818-828.
|
[15] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Receptor discordance between primary breast cancer and liver metastases
[J]. China Oncology, 2023, 33(9): 834-843.
|